echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Suitable for a wide range of tumor types, innovative peptide-conjugated drugs to enhance the effect of immunotherapy

    Suitable for a wide range of tumor types, innovative peptide-conjugated drugs to enhance the effect of immunotherapy

    • Last Update: 2021-10-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cybrexa Therapeutics today announced that preclinical cancer models have demonstrated that the peptide-conjugated drug (PDC) CBX-12 under development can enhance the effectiveness of immune checkpoint inhibitors
    .
    Currently, Cybrexa is conducting a Phase 1/2 clinical trial to determine the tolerability and safety of CBX-12

    .
    The company’s initial focus will be on patients with ovarian cancer and small cell lung cancer (SCLC) overexpressing HER2

    .

    Point inhibitors combined with chemotherapy are standard treatments for many solid tumors, but bone marrow suppression associated with chemotherapy can reduce the efficacy of immunotherapy
    .
    Moreover, due to its influence on normal cells, chemotherapy will also produce various toxic side effects

    .
    Targeted chemotherapy, such as antibody-conjugated drugs (ADC), is limited to the treatment of tumors that express high levels of target antigens

    .

    So, is there any way to specifically target a wide range of tumor types while avoiding toxicity?

    One of the characteristics of all tumors is the acidic microenvironment
    .
    CBX-12 can deliver a potent cytotoxin exatecan specifically to cells in a low pH environment

    .
    It uses a unique variant of a low pH insertion peptide (pHLIP).
    The low pH changes the conformation of this peptide to deliver exatecan into the cell

    .

    This selective targeting of tumor cells' mechanism of action avoids the toxicity associated with the therapy's attack on healthy cells
    .
    Preclinical cancer models show that CBX-12 does not induce bone marrow suppression like chemotherapy

    .

    ▲The mechanism of using low pH insert peptides to deliver anti-cancer drugs to tumor cells (picture source: Cybrexa official website)

    The researchers used a mouse model of colorectal cancer to further evaluate the effect of CBX-12 on the efficacy of PD-1 and CTLA4 immune checkpoint inhibitors
    .
    Experimental results showed that compared with mice that received immune checkpoint inhibitors alone, mice treated with the combination therapy significantly delayed tumor growth, improved survival, and showed complete tumor regression

    .
    Specifically, the combination of CBX-12 and PD-1 inhibitors delayed tumor growth in mice by 4 times, and the combination of CTLA4 inhibitors delayed tumor growth by 10 times

    .

    Not only that, but mice that experienced complete tumor regression also showed long-term immune memory
    .
    Injecting CBX-12-treated tumor cells into mice can cause an anti-tumor immune response, indicating that CBX-12 induces immunogenic cell death

    .

    Dr.
    Gayle also pointed out that since the experiments are carried out in preclinical models, additional studies are needed in the future to understand the impact of this combination therapy on patients

    .

    Reference materials:

    [1] A peptide-drug conjugate that targets the acidic environment of cancer cells may improve the efficacy of immunotherapy.
    Retrieved October 7, 2021, from https:// Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy.
    Retrieved October 7, 2021, from https:// environment-might-enhance-immunotherapy

    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.